News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
735,635 Results
Type
Article (42329)
Company Profile (268)
Press Release (693020)
Multimedia
Podcasts (103)
Webinars (21)
Section
Business (206159)
Career Advice (2046)
Deals (35771)
Drug Delivery (134)
Drug Development (82097)
Employer Resources (174)
FDA (16696)
Job Trends (15104)
News (349496)
Policy (33548)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2624)
Accelerated approval (47)
Adcomms (29)
Allergies (174)
Alliances (50009)
ALS (213)
Alzheimer's disease (1806)
Antibody-drug conjugate (ADC) (457)
Approvals (17067)
Artificial intelligence (667)
Autoimmune disease (295)
Automation (56)
Bankruptcy (362)
Best Places to Work (11688)
BIOSECURE Act (20)
Biosimilars (223)
Biotechnology (175)
Bladder cancer (189)
Brain cancer (73)
Breast cancer (759)
Cancer (5855)
Cardiovascular disease (472)
Career advice (1739)
Career pathing (42)
CAR-T (333)
CDC (57)
Celiac Disease (3)
Cell therapy (904)
Cervical cancer (48)
Clinical research (71229)
Collaboration (2060)
Company closure (5)
Compensation (1389)
Complete response letters (82)
COVID-19 (2798)
CRISPR (109)
C-suite (1119)
Cystic fibrosis (152)
Data (7865)
Decentralized trials (3)
Denatured (28)
Depression (163)
Dermatology (86)
Diabetes (589)
Diagnostics (6948)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (322)
Drug pricing (218)
Drug shortages (31)
Duchenne muscular dystrophy (287)
Earnings (92500)
Editorial (69)
Employer branding (22)
Employer resources (153)
Events (120145)
Executive appointments (1081)
FDA (20414)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1724)
Gene editing (236)
Generative AI (58)
Gene therapy (724)
GLP-1 (1074)
Government (5055)
Grass and pollen (7)
Guidances (408)
Healthcare (19162)
HIV (81)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (289)
Immuno-oncology (93)
Indications (191)
Infectious disease (3137)
Inflammatory bowel disease (218)
Inflation Reduction Act (15)
Influenza (136)
Intellectual property (288)
Interviews (321)
IPO (16716)
IRA (54)
Job creations (3720)
Job search strategy (1444)
JPM (59)
Kidney cancer (19)
Labor market (100)
Layoffs (569)
Leadership (40)
Legal (8103)
Liver cancer (103)
Longevity (32)
Lung cancer (781)
Lymphoma (431)
Machine learning (61)
Management (59)
Manufacturing (1048)
MASH (186)
Medical device (13995)
Medtech (14116)
Mergers & acquisitions (20298)
Metabolic disorders (1513)
mRNA (204)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (414)
Neuropsychiatric disorders (105)
Neuroscience (3317)
Neurotech (1)
NextGen: Class of 2026 (6554)
Non-profit (4576)
Now hiring (78)
Obesity (711)
Opinion (293)
Ovarian cancer (219)
Pain (254)
Pancreatic cancer (299)
Parkinson's disease (361)
Partnered (33)
Patents (596)
Patient recruitment (668)
Peanut (63)
People (59939)
Pharmaceutical (60)
Pharmacy benefit managers (33)
Phase 1 (22157)
Phase 2 (31329)
Phase 3 (23424)
Pipeline (8702)
Policy (327)
Postmarket research (2614)
Preclinical (9441)
Press Release (65)
Prostate cancer (302)
Psychedelics (56)
Radiopharmaceuticals (326)
Rare diseases (1075)
Real estate (6021)
Recruiting (71)
Regulatory (25772)
Reports (56)
Research institute (2431)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (21)
RSV (90)
Schizophrenia (177)
Series A (288)
Series B (215)
Service/supplier (12)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (48)
Startups (3662)
State (2)
Stomach cancer (19)
Supply chain (128)
Tariffs (93)
The Weekly (73)
Vaccines (1109)
Venture capital (108)
Weight loss (463)
Women's health (125)
Worklife (20)
Date
Last 7 days (855)
Last 30 days (3327)
Last 365 days (30088)
2026 (12439)
2025 (30295)
2024 (35371)
2023 (40222)
2022 (51370)
2021 (55968)
2020 (54414)
2019 (46972)
2018 (35354)
2017 (32334)
2016 (31768)
2015 (37790)
2014 (31589)
2013 (26580)
2012 (28784)
2011 (29472)
2010 (27550)
Location
Africa (762)
Alabama (93)
Alaska (7)
Arizona (349)
Arkansas (14)
Asia (40023)
Australia (6575)
California (13257)
Canada (3805)
China (1345)
Colorado (566)
Connecticut (579)
Delaware (405)
Europe (87004)
Florida (1984)
Georgia (426)
Hawaii (3)
Idaho (63)
Illinois (1050)
India (91)
Indiana (600)
Iowa (23)
Japan (537)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (76)
Maryland (1589)
Massachusetts (9453)
Michigan (362)
Minnesota (716)
Mississippi (6)
Missouri (152)
Montana (33)
Nebraska (29)
Nevada (142)
New Hampshire (85)
New Jersey (3488)
New Mexico (29)
New York (3464)
North Carolina (1681)
North Dakota (9)
Northern California (6648)
Ohio (397)
Oklahoma (23)
Oregon (41)
Pennsylvania (2670)
Puerto Rico (29)
Rhode Island (50)
South America (1127)
South Carolina (85)
South Dakota (2)
Southern California (5224)
Tennessee (211)
Texas (2104)
United States (46769)
Utah (393)
Vermont (1)
Virginia (322)
Washington D.C. (80)
Washington State (1062)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
735,635 Results for "astrazeneca canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Breast cancer
AstraZeneca’s breast cancer drug fails to earn backing of FDA advisory committee
Members of the FDA’s Oncologic Drugs Advisory Committee questioned the design of AstraZeneca’s Phase 3 trial of camizestrant, which involved switching treatments at the point of mutation detection, as opposed to the current practice of changing regimens upon disease progression.
May 1, 2026
·
3 min read
·
Tristan Manalac
Earnings
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
After a quarter in which sales topped $15 billion and key readouts went AstraZeneca’s way, the company is increasingly confident that its 2030 revenue target is in reach.
April 29, 2026
·
2 min read
·
Nick Paul Taylor
Pipeline
AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio
While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also elected to take forward a bispecific antibody that destroys the EGFR protein.
April 30, 2026
·
2 min read
·
Tristan Manalac
Adcomms
AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions
In briefing documents released Wednesday, the FDA raises doubts about two AstraZeneca assets set to be discussed Friday at the agency’s first drug-related advisory committee meeting in nine months.
April 29, 2026
·
3 min read
·
Tristan Manalac
Adcomms
Two AstraZeneca Drugs To Be Scrutinized in First FDA Cancer Advisory Panel in 9 Months
The FDA’s cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT inhibitor Truqap in prostate cancer.
March 9, 2026
·
3 min read
·
Tristan Manalac
Lung cancer
AstraZeneca’s ATR Inhibitor Fails To Improve Survival in Phase III Lung Cancer Trial
Ceralasertib is part of AstraZeneca’s ambitious plan to hit $80 billion in revenue by 2030.
December 22, 2025
·
1 min read
·
Annalee Armstrong
GLP-1
Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’
Analysts will be watching as a generic version of semaglutide—marketed by Novo Nordisk as Wegovy for weight loss—launches in Canada as a test case for future price erosion in the U.S.
April 29, 2026
·
3 min read
·
Annalee Armstrong
Business
JPM26: AstraZeneca’s Path to $80B by 2030 Paved With ADCs, Cell Therapies, Near-Term Launches
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs for hypertension, breast cancer and generalized myasthenia gravis, all of which are currently under FDA review.
January 14, 2026
·
2 min read
·
Tristan Manalac
China
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca has risen as one of pharma’s most prolific investors in China, including a $630 million pledge last week for full rights to AbelZeta’s cell therapy for cancer.
January 29, 2026
·
1 min read
·
Tristan Manalac
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.
January 30, 2026
·
2 min read
·
Tristan Manalac
1 of 73,564
Next
